Zhang Yichi, Ojalill Marjaana, Boyer Antonia, Chen Xiao Lei, Tahon Elise, Thivolle Lioux Gaëtan, Xia Marvin, Abbas Maryam, Soylu Halime Meryem, Flieder Douglas B, Connolly Denise C, Molinolo Alfredo A, McHale Michael T, Stupack Dwayne G, Schlaepfer David D
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California.
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Cancer Res Commun. 2024 Dec 1;4(12):3165-3179. doi: 10.1158/2767-9764.CRC-24-0382.
FAK inhibitors are in combinatorial clinical testing with agents that prevent Ras-Raf-MAPK pathway activation in various cancers. This study suggests that nuclear FAK limits ERK/MAPK activation in supporting HGSOC cell survival to cisplatin stress. Overall, it is likely that targets of FAK-mediated survival signaling may be tumor type- and context-dependent.
黏着斑激酶(FAK)抑制剂正在与多种癌症中可阻止Ras-Raf-MAPK信号通路激活的药物进行联合临床试验。本研究表明,细胞核内的FAK限制了ERK/MAPK的激活,从而支持高级别浆液性卵巢癌(HGSOC)细胞在顺铂应激下的存活。总体而言,FAK介导的生存信号通路的靶点可能因肿瘤类型和具体情况而异。